www.regonline.co.uk/antibiotic2014
This event has an open oral and poster session.
Abstract can be submitted on any subject related to antibiotic alternatives
Abstracts for poster presentation only can be submitted up to two weeks before the event.
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the disappointingly low rate of emergence of new,clinically useful antibiotics, has refocused attention on finding alternatives to antibiotic treatments. This event will discuss the potential utility of phages, probiotics, antimicrobial peptides, herbal medicines and immune modulation for treating human and animal disease. This event has CPD accreditation.
Talks Include:
Novel Host Therapeutic Targets regulating M.tuberculosis infection
Mr Cornelis Korbee, PhD Student, Leiden University Medical Center, The Netherlands
Pro- & Synbiotics - an alternative to antibiotics?
Professor Stig Bengmark, Honorary Visiting Professor, Division of Surgery & Interventional Science, University College London, UK
HBD3 regulates matrix metalloproteinase production in human myeloid dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB)
Professor Kim A. Brogden, Director, Dows Institute for Dental Research, The University of Iowa, USA
Quorum sensing inhibitors as an alternate to conventional antibiotics
Dr. Pragasam Viswanathan, Associate Professor, VIT University, India
TBC
Dr Matthew Dryden MD FRCPath, Southampton University School of Medicine, Southampton, UK
Antibiotic versus maggot therapy in diabetic foot ulcer
Professor Chumpon Wilasrusmee, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
Development of bacteriocins for therapy of infections caused by Gram positive and negative MDR pathogens
Dr Mathew Upton, School of Biomedical & Healthcare Sciences, Plymouth University, Plymouth, UK
Bacteriophages for antistaphylococcal therapies - natural repertoire and limitations of choice
Dr. Malgorzata Lobocka, Institute of Biochemistry and Biopysics of the Polish Academy of Sciences, and Autonomous Department of Microbial Biology, Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Poland
From Host-defense peptides to new antimicrobial agents
Dr Paul R. Hansen, University of Copenhagen, Denmark
Anti-microbial cationic peptides as a strategy for innovation in global health therapeutics for human infectious diseases
Dr Hussin Rothan, Researcher, Faculty of Medicine, University of Malaya, Kuala Lumpur , Malaysia
Antibodies as a limitless source of peptides with innate microbicidal and immunomodulatory activity (ultrabodies)
Professor Luciano Polonelli, Full University Professor, University of Parma, Italy
Octapeptins revisited
Dr Tony Velkov, Monash Institute of Pharmaceutical Sciences, Victoria, Australia
Using molecular simulations to understand the dual action of peptides in antimicrobial activity and innate immune modulation
Dr Peter J Bond, Principal Investigator Bioinformatics Institute, A*STAR, Singapore. Adjunct Assist. Professor, Dept. Biological Sciences, National University of Singapore, Singapore
Preclinical development of a novel synthetic antimicrobial peptide for lung infections and sepsis
Dr Alessandro Pini, Dept. of Medical Biotechnology, University of Siena, SetLance srl Toscana Life Sciences, Italy
Enhancing Host Resistance against Lethal Infections
Professor Roger M. Loria, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
Echinoderms as source of novel antimicrobial peptides to contrast human pathogens
Dr Domenico Schillaci, Lecturer, University of Palermo, Palermo, Italy
War against Microbes: are Antibiotics the only Weapons?
Dr. Jayanta Haldar, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
Antibiotics in Modulation of M1 and M2 Macrophage Responses
Dr Charles Mills, BioMedical Consultants, USA
Probiotic bacteria against multiresistant pathogens
Professor Iryna Sorokulova, Auburn University, Auburn, AL, USA
Antibiotic therapy corroborated by selected immunomodulating beta blockers
Dr. Karin Peuschel, CNP, Switzerland
The potential use and delivery of bacteriophages for the treatment of Staphylococcus aureus wound biofilm infections
Diana R. Alves, University of Bath, UK
Clinical Application of Probiotics in Antibiotic Therapy: the Current and Future Use
Dr Thomas A. Tompkins, Research Director, Lallemand Health Solutions Inc, Montreal, Canada
www.regonline.co.uk/antibiotic2014
Tags: adjunctive therapy, alphaviruses, Androstenes; Steroids; Infection; viral and bacterial :Immune regulation, antagonistic activity, anti-microbial agents, Antiarthritis, antibiotic, antibiotic alternatives, antibiotic resistance, antibiotic time, antibiotic-resistant pathogens, Antibiotics, antibodies, Antiinflammatory, antimicrobial peptides, auto-inducers, Bacillus probiotic, bacteria, bacteriophage, bees, biofilms, Campylobacter, cGMP, chronic wound, clinical trials, Clostridium difficile, device associate infection, diabetic foot ulcer, diagnostic, ecology, EMA, FDA, flaviviruses, Free oxygen radicals, gastrointestine, genomes, Genomics, herbal, histidine kinase inhibitors, honey and wounds, host, Immunomodulators, immunoregulation, infection, Innate Immunity, Lactobacilli, lung, macrophage, Macrophages, Maggot wound therapy, Metabolism, Metagenomics, microbial functioning, MRSA, mult-drug resistance, Multi-drug resistant bacteria, Nitric Oxid, octatpeptins, peptides, phage nanobiotechnology., phage therapy, phage-bacteria interactions, phagosome, polymyxins, poultry, probiotic, Probiotics, Pseudomonas aeruginosa, Purification Monolith, Quorum senser, regulation, Resistance, Scaleable, Serendipity, signalling, staphylococcal biofilms, Staphylococcus aureus, Surgihoney, therapeutic, therapeutic use, Toxin, tuberculosis, two-component signal transduction, WalK, Wound healing, wouund healing, Yield
Follow Us!